Whereas VEGF-A, PDGF-AB, FGF-2 and EGF show weak bypassing potential in addition to either crizotinib or canertinib, addition of HGF shows strong bypassing potential by significantly bypassing the growth-inhibitory effects of canertinib in medulloblastoma cells (Fig 4D–4M). The gene discussed is FGF2; the disease is medulloblastoma.